When The Canberra Times reported in February 2022 that Stuart Kennedy had gotten out of bed one morning before his parents and made his own breakfast, the detail could easily have slipped past most readers. Teenagers making toast is not news. But for a boy who had spent the better part of three years barely able to stand unassisted, it was the first solid evidence that something had actually changed.
It is worth sitting with Stuart’s story a while longer, not just because it is a story of persistence and a family that refused to accept “there’s nothing more we can do,” but because the shape of his recovery is unusual even among the small number of documented flumazenil cases. Where some patients describe an almost instant return to alertness after starting the drug, Stuart’s turnaround unfolded gradually, over days, following a slow low-dose approach that has also shown up in other published case reports of flumazenil used for GABA-related hypersomnia. For a while, nothing seemed to be happening at all. Then, bit by bit, the fog started to lift.
That detail matters clinically. It suggests that for at least some patients, flumazenil may need to be titrated carefully and given time to work, rather than judged a failure after a day or two of no visible effect. It also offers a sliver of hope to families who might otherwise give up on a treatment too early, simply because the “lightbulb moment” other patients describe doesn’t happen for them.
How It Started: A Virus That Never Really Ended
Stuart’s decline began in 2016, during Year 7 at Canberra Grammar School, with what looked like an ordinary virus. Most kids bounce back from that kind of thing within a couple of weeks. Stuart didn’t. Instead of recovering, he began sleeping longer and longer, eventually stretching to 16 or 18 hours a day, and still waking up exhausted.
By the start of the 2017 school year, it had become a full-blown crisis. His parents, Anne and Neil Kennedy, could barely rouse him in the mornings. What sleep researchers call “sleep inertia,” that groggy, disoriented feeling most people shake off within a few minutes of waking, never lifted for Stuart. It just continued, hour after hour. Brain fog set in. His muscles began to waste from disuse. Ordinary tasks most teenagers do without thinking became, for him, close to impossible.
Getting a Name for It
Eventually, after a long string of medical appointments, Stuart underwent an overnight sleep study, followed by a Multiple Sleep Latency Test (MSLT), the standard diagnostic tool used to measure how quickly someone falls asleep during a series of scheduled daytime naps and whether they slip into REM sleep abnormally fast. Doctors at the Canberra Sleep Clinic diagnosed him with idiopathic hypersomnia. A second sleep study in Sydney confirmed it.
“Idiopathic” is a word doctors use when they know what a condition looks like but not what causes it, and that is exactly where IH sits. According to the National Institutes of Health’s Genetic and Rare Diseases Information Center, people with IH struggle to stay alert during the day no matter how much they sleep at night, and extending their nighttime sleep does nothing to fix it. The Sleep Foundation notes that some researchers now suspect an autoimmune or post-viral trigger in certain cases, and that some experts believe the disorder may involve heightened activity of nerve cells carrying GABA-A receptors, the same receptors targeted by sedatives and, as it happens, by flumazenil itself.
IH belongs to a family of conditions called central disorders of hypersomnolence, which also includes narcolepsy. The two are often confused, but they aren’t the same thing. Narcolepsy, particularly Type 1, typically involves sudden muscle weakness known as cataplexy, along with sleep paralysis and vivid hallucinations at the edges of sleep. IH doesn’t usually come with those dramatic sleep attacks; instead, it drags a person down into long, heavy, unrefreshing sleep and keeps them there. A 2024 systematic literature review published in Sleep Advances found that IH remains genuinely difficult to pin down, with patients often waiting years for an accurate diagnosis because it overlaps so heavily with narcolepsy type 2 and because objective testing hasn’t kept pace with the complexity of the condition.
For Stuart, getting a diagnosis was really only the beginning. Stimulant medications commonly prescribed for daytime sleepiness, including Ritalin and Concerta, gave him some relief but nothing close to a solution. Over the course of Years 8 through 10, he missed nearly three years of formal schooling, an enormous setback for a young teenager trying to build a foundation for the rest of his education.
A Father Who Wouldn’t Stop Looking
Neil Kennedy, Stuart’s father, wasn’t willing to accept that the family had run out of options. He started digging into research literature and specialist clinics well beyond Canberra, eventually connecting with the Emory University Sleep Clinic in Atlanta, Georgia, whose researchers had been quietly building a body of work on GABA-related hypersomnolence for years. There, Dr. David Rye suggested that Stuart might be a reasonable candidate for a trial of flumazenil.
Flumazenil isn’t a drug most people have heard of unless they work in emergency medicine. Ordinarily it is used intravenously to reverse the effects of a benzodiazepine overdose, essentially flipping sedation off by blocking the receptors that benzodiazepines and, some researchers believe, an unidentified endogenous compound act on in patients with IH. Using it as an ongoing daily treatment for chronic hypersomnia is well outside its approved use, and access to it required special arrangements. Canberra Sleep Clinic director Dr. Stuart Miller secured permission to import flumazenil in powder form, which a compounding chemist in Adelaide then turned into lozenges Stuart could dissolve under his tongue each morning and evening.
Published research backs up why Rye and Miller were willing to try it. A case report in the Journal of Psychopharmacology described a patient with IH whose excessive sleepiness, sleep drunkenness, and cognitive complaints eased substantially after a continuous low-dose flumazenil infusion followed by a slow-release implant. A larger retrospective study covering 153 patients, published in the Journal of Clinical Sleep Medicine and led by researchers including Rye himself, found that compounded flumazenil formulations, including sublingual lozenges like the ones Stuart used, produced meaningful improvement in a substantial share of people with treatment-resistant hypersomnolence. It remains an off-label, largely experimental approach, and access is limited, but for families who have exhausted the standard options, that body of evidence is more hope than most had before.
The Slow Return
At first, nothing seemed to be happening. Stuart kept taking the lozenges, and for several days there was no visible change, which is exactly the kind of stretch that tests a family’s patience and hope in equal measure. Then, gradually, something shifted. He described waking up one morning without the crushing sluggishness that had defined his mornings for years. The headache was still there, but the fog behind his eyes had thinned.
By the fifth day, the change was unmistakable. Stuart woke up before his parents, something that hadn’t happened in years. Rather than drifting back to sleep the way he almost always had, he stayed up. He wandered into the kitchen and made his own breakfast without anyone prompting him. He tidied up around the house. Later that same day, his parents found him outside in the yard, tossing a ball to the family’s old English Sheepdog, an entirely unremarkable scene for most families and an almost unbelievable one for the Kennedys.
Neil has described the moment his son turned to him and said he could think clearly again, that the fog was gone, that he wasn’t tired. After watching his son spend more than two years largely confined to bed, at times unable to stand without help, it was, in Neil’s words, like getting him back.
Rebuilding, One Semester at a Time
Recovery from years of missed development doesn’t happen overnight just because a medication starts working. Stuart returned to school part-time in Year 10, and on the advice of specialists, he moved into Canberra Grammar’s boarding house, in part to help him rebuild a structured daily routine that his body had lost the habit of.
It wasn’t smooth. He started out earning Cs and Ds, a long way from where he’d been academically before the illness took over. But with support from teachers and learning assistants, and with his own stamina slowly returning, he began to climb. In software design in particular, he moved from 11th in his class up to 6th, a trajectory that eventually helped him secure an unconditional offer to study software engineering at the University of Canberra through his school’s recommendation scheme.
Why This Story Matters Beyond One Family
Sleep disorders are more common, and more commonly missed, than most people assume. A 2019 Australian parliamentary inquiry found that roughly one in five Australians live with a significant sleep disorder, and a large share of those cases go undiagnosed for years. Dr. Miller has pointed out that a teenager sleeping more than ten hours a night on a regular basis is a signal worth taking seriously, not dismissing as ordinary adolescent laziness.
The broader research picture backs this up. Multiple reviews, including one from PMC/NIH, note that while modafinil and armodafinil remain the first-line, evidence-backed treatments for IH, a meaningful number of patients don’t respond adequately to them, which is exactly the gap that experimental approaches like flumazenil are trying to fill. The National Organization for Rare Disorders also tracks IH as an underrecognized condition, splitting it into subtypes with and without unusually long sleep time, and pointing patients and families toward NIH’s GARD program for further support.
Stuart’s case is a reminder that progress in a rare, poorly understood illness rarely looks like a single dramatic cure. More often it looks like a father spending months on the phone with clinics on the other side of the world, a doctor willing to import an unconventional medication through the proper channels, and a teenager who kept showing up to class even after starting from Cs and Ds. It is also a reminder that a breakthrough doesn’t have to announce itself with fireworks. Sometimes it looks exactly like a kid making his own breakfast before anyone else in the house is even awake.
Frequently Asked Questions
1. What is idiopathic hypersomnia (IH)? IH is a chronic neurological sleep disorder marked by excessive daytime sleepiness and difficulty waking, despite what looks like adequate or even excessive nighttime sleep. Unlike narcolepsy, it typically does not involve cataplexy or the REM sleep abnormalities associated with that condition.
2. How is idiopathic hypersomnia diagnosed? Diagnosis usually involves an overnight polysomnography study to rule out other causes like sleep apnea, followed by a Multiple Sleep Latency Test to measure how quickly someone falls asleep during the day and whether they enter REM sleep too fast, which would point toward narcolepsy instead.
3. How is IH different from narcolepsy? Narcolepsy, especially Type 1, involves sudden muscle weakness (cataplexy), and often sleep paralysis or hallucinations. Type 2 narcolepsy lacks cataplexy and can be harder to distinguish from IH, but people with narcolepsy tend to enter REM sleep unusually quickly on an MSLT, a pattern that IH patients don’t typically show.
4. What treatments exist for idiopathic hypersomnia? There’s no cure yet. Stimulants such as modafinil and armodafinil are the standard first-line treatments and have the strongest clinical trial evidence behind them. Some patients try sodium oxybate or oxybate combinations like Xywav. Others, when standard options fail, explore flumazenil, still considered experimental and used off-label.
5. How does flumazenil help with IH? Flumazenil is normally used to reverse benzodiazepine overdoses by blocking GABA-A receptors. Some researchers believe certain IH patients have an overactive natural compound acting on those same receptors, and that flumazenil can counteract it. Response varies widely: some patients report fast improvement, others, like Stuart, see it unfold gradually over days.
6. What’s the difference between excessive daytime sleepiness and ordinary fatigue? Excessive daytime sleepiness is a persistent, hard-to-resist urge to sleep during the day even after a full night’s rest. Ordinary fatigue is more about low energy and doesn’t necessarily come with an overwhelming pull toward sleep itself.
7. What does the Multiple Sleep Latency Test actually measure? It tracks how many minutes it takes a person to fall asleep across several scheduled nap opportunities during the day, and whether they enter REM sleep abnormally quickly. It’s one of the main tools used to tell IH, narcolepsy, and other hypersomnia disorders apart.
8. Is flumazenil available as a standard prescription for IH? No. It isn’t approved for this use and is only available through specialist clinics willing to prescribe it off-label, often via compounded formulations. More research is needed before it becomes anything close to mainstream.
9. What else can cause excessive sleepiness? Narcolepsy type 2, sleep apnea, certain parasomnias, mood disorders, and other central disorders of hypersomnolence can all produce similar symptoms, which is part of why an accurate diagnosis for IH can take years.
10. How can parents spot a possible sleep disorder in a teenager? Regularly sleeping more than 10 hours a night, extreme difficulty waking, persistent daytime grogginess, and fatigue that doesn’t improve no matter how much sleep a teen gets are all signs worth raising with a doctor, ideally with a referral to a sleep specialist.
11. What role does GABA play in IH? GABA is the brain’s primary calming neurotransmitter. Some researchers suspect that in certain IH patients, something is over-activating GABA-A receptors, producing the extreme sleepiness and grogginess that defines the condition. That theory is part of what makes flumazenil, a GABA-A receptor blocker, a candidate treatment.
12. What lifestyle changes can support IH treatment? A consistent sleep-wake schedule, minimizing naps, avoiding alcohol and sedatives, and getting regular exposure to daylight can all help alongside medication, though they generally aren’t enough on their own for most people with IH.
References
- Stuart Kennedy overcame a rare sleep disorder to get a place at university, The Canberra Times
- What is Idiopathic Hypersomnia?, Sleep Foundation
- Idiopathic Hypersomnia, GARD, National Institutes of Health
- Idiopathic Hypersomnia, National Organization for Rare Disorders
- Idiopathic Hypersomnia, PMC, National Institutes of Health
- Idiopathic Hypersomnia, StatPearls, NCBI Bookshelf
- Diagnostic challenges and burden of idiopathic hypersomnia: a systematic literature review, Sleep Advances
- Use of subcutaneous flumazenil preparations for the treatment of idiopathic hypersomnia: A case report, Journal of Psychopharmacology
- Update on the treatment of idiopathic hypersomnia: Progress, challenges, and expert opinion, ScienceDirect
- Xywav: A Treatment Option for Idiopathic Hypersomnia in Down Syndrome, PMC
- Multiple Sleep Latency Test, Sleep Foundation
- Emory University Sleep Clinic, Emory School of Medicine
- University of Canberra
